Plot showing non-essential (black) and essential (red) genes in melanoma cells, based on CRISPR/Cas9 screening.

Daniel Peeper

Functional oncogenomics for tumor & immunotherapy

Tumor heterogeneity, immune dysfunction and therapy resistance are among the most substantial challenges that limit durable benefit of cancer therapies. Using powerful function-based genomics, we screen for novel therapeutic targets to tackle those clinical problems.

We develop rational combinatorial cancer treatments, which target both cancer and immune cells, thereby simultaneously eliminating the patient’s tumor and harnessing the immune system. This has already culminated in new concepts that we are translating to the benefit of the patient.

On this page we’re sharing some of the highlights of our lab, news items, our research, team members and, if you scroll to the bottom, our vacancies.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.